The Med-Tech company PolarCool AB (publ.) secures a league agreement with the Czech Republic’s top-tier hockey league, Extraliga, for the remainder of the 2025 Playoffs. The agreement ensures PolarCap® will be provided during the 2025 playoff semi-finals and finals.

The agreement with the Extraliga marks a strategic step toward full-scale adoption next season and aligns with PolarCool’s long-term goal of securing partnerships in Europe’s top-tier leagues and positioning PolarCap® as the standard in acute concussion management.

This pilot phase will showcase how PolarCap® serves as a valuable enhancement to existing concussion management, providing valuable insights to teams and medical staff across the league.

PolarCool's CEO Erik Andersson comments:

-We are delighted with the partnership with the Extraliga. It is an important step towards a broader collaboration, reinforcing our dedication to improving player safety in one of Europe’s most competitive hockey leagues. By introducing PolarCap® during the high-stakes play-off phase, we are certain that the benefits of our technology will be showcased and pave the way for a full league-wide implementation next season.

Gaining league approval for the Extraliga Playoffs marks another strategic step forward for PolarCool in the Czech Republic. In early 2025 ice hockey club BK Mláda Boleslav became the first club to sign a commercial agreement in the market.

For more information

Erik Andersson –  CEO PolarCool AB (publ.)               
+46 - 738 60 57 00                                         
E-mail: erik.andersson@polarcool.se

About PolarCool AB (publ.)

PolarCool AB (publ.) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap®. PolarCool AB (publ.) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.